There has been a sudden surge. After the close of trading on the 7th, there was buying interest in anticipation of future progress as they announced their goal of starting phase 1 clinical trials for the developing allergy vaccine, 'FPP004X', in the first quarter of the fiscal year ending December 2025. The same company has signed an option contract for FPP004X with Shionogi & Co., Ltd., and holds the option right to acquire exclusive research and development and commercialization rights for all diseases worldwide.
ファンペップ---急騰、アレルギーワクチンの第1相臨床試験開始時期を公表
Fanpep - skyrocketing, announced the start time of the Phase 1 clinical trial of allergy vaccine.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.